Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2015

View Archived Issues

Ferring acquires assets of orthopedic biomaterial developer BioSET

Propanc starts animal studies of proteolytic proenzymes for cancer

RepliCel Life Sciences submits clinical trial application for RCS-01

ZP-GA-1 shows similar PK characteristics to native glucagon

Marathon sells non-strategic products to focus on treatments for rare diseases

Merck Serono and Sysmex Inostics announce opening of liquid biopsy RAS biomarker testing center

Cyclenium Pharma and Fundacion Medina form drug discovery agreement

Xeris Pharmaceuticals presents comparative PK/PD study of G-Pump and GlucaGen

Plasma kallikrein inhibitors disclosed in Kalvista Pharmaceuticals patent

U. S. researchers develop recombinant N. meningitidis factor H binding proteins

Isis reports chemically modified ssASOs targeting ataxin-3

Galapagos patents CFTR modulators

Takeda patent reveals prokineticin PKR1 receptor antagonists

New orexin receptor antagonists disclosed by Merck & Co.

Saroglitazar reverses biochemical manifestations of metabolic syndrome

Nobelpharma launches Zanosar i.v. infusion in Japan

Axitinib shows activity against mutant BCR-ABL1 leukemia

Eisai's phase III trial of eribulin in soft tissue sarcoma meets primary endpoint

AstraZeneca and Orca Pharmaceuticals partner to discover ROR gamma inhibitors

Isis Pharmaceuticals announces phase I results for prekallikrein inhibitor for HAE

Phase I results indicate ALKS-7106 does not warrant further development

Neurotrope releases topline results from phase IIa trial of bryostatin 1 for Alzheimer's disease

First patient treated in trial of Renevia in HIV-associated lipoatrophy

Eisai reports results from phase II trial of lenvatinib in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.